|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Outcome variables were: a) liver fibrosis (Metavir score) [fibrosis stage (F0, F1, F2, F3 and F4) and advanced fibrosis and cirrhosis (F ≥ 3 and F4, respectively)]; b) non-invasive indexes [FIB-4, APRI, and their cut-offs (FIB-4 ≥ 3.25 and APRI≥1.5)]; c) inflammation-related biomarkers (leptin, HGF, NGF, sFasL, sFas, MIF, HA, Ang-2, TIMP1, MMP1 and MMP2).
|
30336268 |
2019 |
|
Liver Cirrhosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
They also exhibited a significantly greater repair potential in relation to cirrhosis pathology and impaired liver function than did DPSCs expressing HGF at physiological levels.
|
29150644 |
2017 |
|
Liver Cirrhosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aberrant autophagy in liver cirrhosis resulted in hepatocyte growth factor (HGF) expression, leading to activation of Met/JNK and Met/STAT3 signaling in sorted hepatic Axin2/EGFP+ cells and their transition into Axin2/EGFP+CD90+ cells that possess CSC properties.
|
28783177 |
2017 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, our study suggests that suppression of miR-26a-5p in MSCs may improve their therapeutic effects against cirrhosis through increasing HGF production.
|
28386375 |
2017 |
|
Liver Cirrhosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adenoviral delivery of truncated MMP-8 fused with the hepatocyte growth factor mutant 1K1 ameliorates liver cirrhosis and promotes hepatocyte proliferation.
|
26527860 |
2015 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transplantation of bone marrow MSC in combination with HGF-CNP could be an ideal approach for the treatment of liver cirrhosis.
|
21526984 |
2011 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concentrations of TNF-α (median 15.0 vs. 25.1 pg/ml, area under the receiver operating characteristic curve [AUC] 0.91), IL-8 (48.7 vs. 103.3 pg/ml, AUC 0.85), IP-10 (176 vs. 566 pg/ml, AUC 0.83), MCP-1 (449 vs. 735 pg/ml, AUC 0.78), suPAR (3.5 vs. 5.2 ng/ml, AUC 0.78), MIG (100 vs. 152 pg/ml, AUC 0.75), and HGF (3.69 vs. 5.58 ng/ml, AUC 0.71) were significantly higher in patients with cirrhosis.
|
21229279 |
2011 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mesenchymal stem cells (MSCs) can prevent the development of liver fibrosis, and hepatocyte growth factor (HGF) can also attenuate liver cirrhosis.
|
20025519 |
2010 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrated the therapeutic efficacy of adenovirus-mediated HGF and TbetaTR gene transduction after partial hepatectomy for liver cirrhosis.
|
16627068 |
2006 |
|
Liver Cirrhosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF.
|
16958060 |
2006 |
|
Liver Cirrhosis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Effects of hepatotrophic factors on the liver after portacaval shunt in rats with portal hypertension.
|
17097021 |
2006 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, inhibitory and apoptotic effects of adenoviral HGF gene transduction in hepatomas in contrast to potent mitogenic and antiapoptotic effects of HGF for hepatocytes are not only of biological interest, but also pose clinical benefits for adenoviral HGF gene therapy for CH and LC.
|
15942646 |
2005 |
|
Liver Cirrhosis
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
A positive correlation between platelet count in liver cirrhosis and serum level of thrombopoietin (r - 0.35, p<0.05) and hepatocyte growth factor (r - 0.48, p<0.01) was observed.
|
15239259 |
2004 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis.
|
12907947 |
2003 |
|
Liver Cirrhosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although further study is necessary, the high serum level of HGF revealed high carcinogenic states in chronic hepatitis and liver cirrhosis type C.
|
11223718 |
2001 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, HGF gene therapy may be potentially useful for the treatment of patients with liver cirrhosis, which is otherwise fatal and untreatable by conventional therapy.
|
9930873 |
1999 |
|
Liver Cirrhosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
No reports have been published about the localization of HGF mRNA in human liver cirrhosis.
|
8888442 |
1996 |
|
Liver Cirrhosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mean values for serum HGF in acute hepatitis (AH), chronic hepatitis (CH), liver cirrhosis (LC), hepatocellular carcinoma (HCC), primary biliary cirrhosis (PBC), fulminant hepatic failure (FHF), and normal controls were 0.45, 0.40, 1.05, 1.06, 0.44, 16.40, and 0.27 ng/mL, respectively.
|
7806142 |
1995 |